The value of a human life
Business Standard|June 20, 2024
Economics and science have created injustices that legal systems cannot solve. Two looming problems are climate change and ageing societies
ARUN MAIRA
The value of a human life

Modern economics has become a contest between human values and economic valuations, caused by two conceptual problems. One is the utilitarian principle. The other is the impossibility of quantifying a human life. Economic cost-benefit valuations have corrupted human values, as well as public policies and legal processes.

A good policy, according to the utilitarian principle, benefits the maximum number of people, even if it harms a minority. Utilitarian policies are politically popular because a majority favours them. The utilitarian principle does not protect the rights of marginalised people, whose needs are trampled upon in the march of economic growth. Political and economic majoritarianism are natural partners. A majority persuaded that it will be economically better off turns away from the needs of those left behind. The majoritarian principle may be good for electoral politics, but it limits a democracy. In a majoritarian democracy, not only are the majority better off, they can be persuaded they are inherently better people too.

The benefits and losses must be quantified to compute overall gains and weigh losses amongst sections of society. The application of cost-benefit analysis put economists in the driving seat of policymaking in the last century, explains Binyamin Appelbaum in The Economists' Hour: How the False Prophets of Free Markets Fractured Our Society. Economists were able to persuade political leaders to apply cost-benefit analysis to evaluate the impacts of regulations and take supposedly rational decisions. In the 1960s, the US government weighed costs of weapon systems against the values of lives destroyed in the Vietnam War. In 1971, the US President asked the government to weigh the economic costs and benefits of environmental protection.

この記事は Business Standard の June 20, 2024 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Business Standard の June 20, 2024 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BUSINESS STANDARDのその他の記事すべて表示
Technology changes BFSI sector
Business Standard

Technology changes BFSI sector

Firms in the industry are undergoing a major digital transformation, with technologies - Cloud, Al, GenAI, RPA, and blockchain - leading the way, says a Business Standard-Everest Group report

time-read
7 分  |
November 06, 2024
Making sense of India's real estate boom
Business Standard

Making sense of India's real estate boom

Growth drivers in real estate include urbanisation, disposable incomes, and demand for residential, commercial, and logistics spaces, according to a Business Standard-Knight Frank report

time-read
8 分  |
November 06, 2024
Business Standard

THE BIGGEST BFSI SUMMIT IS EVEN BIGGER NOW

The largest financial sector event in the country - the Business Standard BFSI Insight Summit - is back this year in a bigger form.

time-read
3 分  |
November 06, 2024
Shares of Adani Ports anchor at 5-month low
Business Standard

Shares of Adani Ports anchor at 5-month low

Down 5% in two days after business update for October

time-read
2 分  |
November 06, 2024
Business Standard

Markets rebound as investors cast wide net for value

In-demand financial stocks drive the rally

time-read
2 分  |
November 06, 2024
Business Standard

Global mkt: Stocks, Treasury yields gain as US votes

World stocks rose and Treasury yields rebounded on Tuesday while an index of market volatility retreated, as markets awaited early indications of the outcome of a knife-edge US election, with only currency markets showing some jitters.

time-read
1 min  |
November 06, 2024
Business Standard

Upper-teens EPS growth likely for Gland Pharma in next two financial yrs

Gland Pharma's Q2FY25 results beat muted expectations, with upper-teens EPS growth projected over the next two financial years despite a slowdown in US sales and temporary issues at its Cenexi subsidiary.

time-read
2 分  |
November 06, 2024
Sagility India IPO booked 22% on Day 1
Business Standard

Sagility India IPO booked 22% on Day 1

The initial public offering (IPO) of Sagility India Ltd, a technology-enabled services provider in the health care space, received 22 per cent subscription on the first day of bidding on Tuesday.

time-read
1 min  |
November 06, 2024
Record FPI exodus throws a shadow on stock markets
Business Standard

Record FPI exodus throws a shadow on stock markets

Foreign investors are souring on India's stock market, selling a record amount of shares amid signs the South Asian nation's post-pandemic economic boom is losing steam.

time-read
1 min  |
November 06, 2024
Govt may divest 2.5% in HZL through OFS
Business Standard

Govt may divest 2.5% in HZL through OFS

The Centre is planning to sell 2.5 per cent of the total share capital of Hindustan Zinc Ltd (HZL) through an offer for sale (OFS) on Wednesday and Thursday for ₹505 per share.

time-read
1 min  |
November 06, 2024